Advertisement
News
Advertisement

The agreement enables Win-Med to market ETView's VivaSightT airway management platform in northern Italy.

Tue, 06/19/2012 - 4:45am
The Associated Press

TEL AVIV, Israel--(BUSINESS WIRE)--Jun 19, 2012-- ETView Medical Ltd.

(TASE: ETVW) announced today that it has entered into a distribution agreement with Win-Med Co., Ltd. (Win-Med). The agreement enables Win-Med to market ETView's VivaSight(TM) airway management platform (previously known as TVT(TM)), in northern Italy for a period of 2 years. Other terms were not disclosed.

William Edelman, CEO of ETView Medical, commented, "We are excited to add Win-Med to our expanding distributor network." Mr. Edelman continued, "VivaSight(TM) is currently being distributed across Europe, Asia and the United States. VivaSight(TM) provides best-in-class airway management solutions for sophisticated thoracic surgical procedures requiring lung isolation." On June 4, 2012, ETView announced the appointment of David Amar, MD, to its Scientific Advisory Board.

On May 23, 2012, ETView announced US FDA clearance of a 510(k) Pre-Marketing Notification Application for the VivaSight(TM)-DL line of innovative airway devices.

About the VivaSight(TM) Airway Management System VivaSight(TM)1 is a proprietary, single-use disposable medical device, consisting of either a single lumen (VivaSight(TM)-SL) or a dual lumen (VivaSight(TM)-DL) airway ventilation tube with an integrated continuous high resolution video airway imaging system permitting airway control and lung isolation during certain surgical procedures.

Lung isolation is employed to provide one-lung ventilation in patients undergoing thoracic, cardiac, vascular, or esophageal surgeries2.

During lung isolation, temporary visualization of the patient airway is achieved with a fiberoptic bronchoscope while the patient is ventilated and the target lung isolated. Intra-operative surgical maneuvers often require repeated imaging and partial blocking of the airway to maintain lung isolation.3 It is estimated that over 1.9 million lung isolation procedures are conducted worldwide annually,4 accounting for over $250M in single-use medical disposables.5 ETView has pioneered development of the VivaSight(TM) platform, combining an airway ventilation tube with integrated continuous high resolution airway imaging for patient airway control and lung isolation capability (eliminating the need for fiberoptic bronchoscope6 imaging during these procedures).

About Win-Med Co., Ltd.

According to information provided to the company, Win-Med Co., Ltd.

was founded in 2012 by senior medical technology sales and marketing executives. Win-Med currently markets and distributes medical devices for use in the ICU, ENT, Gastroenterology and Orthopedics departments of leading healthcare institutions throughout northern Italy.

Headquartered in Fosso, Italy, Win-Med focuses on business development and regional country wide marketing via a network of clinical support staff and experienced sales executives.

About ETView Medical Ltd.

ETView Medical Ltd. (TASE: ETVW) has successfully combined airway management with continuous direct airway visualization for medical professionals. ETView's patented VivaSight(TM) airway management portfolio consists of single-use disposable medical devices, representing either single or double lumen ventilation tubes with an integrated continuous high resolution airway imaging system.

VivaSight(TM)-SL and VivaSight(TM)-DL are currently sold in Europe, Israel, and the US to overcome current limitations and associated adverse surgical events during lung isolation surgeries.7 Forward-Looking Statement The Company estimations in this press release, including those estimations regarding the Company's predicted scope of business, constitute forward-looking statements, as such term is defined under the Israeli Securities Law (5728-1968), and there is no certainty that such estimations shall materialize. The Company's estimations are based on business assumptions, prior experience, and professional data. Due to various factors, foreseen and unforeseen, including, but not limited to, changes in market trends, competition, global or local economic conditions, and amendments of regulation, such estimations may not materialize in whole or in part, or materialize in a substantially different manner than anticipated by the Company.

1 Patents Issued and Pending2 Principles and Practices of Anesthesia for Thoracic Surgery. P. Singer (ed.) 20113 Anesthesia & Analgesia.

2009;108:1097-1014 National Health Statistics Reports Number 29, October 26, 20105 Company estimates on file6 Minerva Anestesiol.

2009;75(Suppl 1):1-47 Anesthesiology. 2006;105:471-477 CONTACT: ETView Medical Ltd.

Bill Edelman, CEO Worldwide: +1 567 248 4821 In Israel: +972 72 260 7060 bill.edelman@etview.com www.etview.com KEYWORD: UNITED STATES EUROPE NORTH AMERICA NEW YORK MIDDLE EAST ISRAEL ITALY INDUSTRY KEYWORD: SURGERY HEALTH MEDICAL DEVICES SOURCE: ETView Medical Ltd.

Copyright Business Wire 2012 PUB: 06/19/2012 08:14 AM/DISC: 06/19/2012 08:14 AM http://www.businesswire.com/news/home/20120619005925/

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading